- Home
- BCAB vs SCNX Comparison
BCAB vs SCNX Comparison
Compare BCAB & SCNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BCAB | SCNX |
|---|---|---|
| Founded | 2007 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Other Pharmaceuticals |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.8M | 24.8M |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | BCAB | SCNX |
|---|---|---|
| Price | $0.19 | $0.45 |
| Analyst Decision | Hold | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $1.00 | N/A |
| AVG Volume (30 Days) | ★ 3.1M | 1.5M |
| Earning Date | 11-13-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $653,391.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 207.88 |
| 52 Week Low | $0.14 | $0.43 |
| 52 Week High | $1.43 | $3.90 |
Technical Indicators
Market Signals| Indicator | BCAB | SCNX |
|---|---|---|
| Relative Strength Index (RSI) | 27.25 | 34.54 |
| Support Level | $0.14 | $0.43 |
| Resistance Level | $0.39 | $0.51 |
| Average True Range (ATR) | 0.05 | 0.04 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 22.20 | 10.90 |
Price Performance
Historical ComparisonAbout BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.
About SCNX Scienture Holdings Inc.
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on providing value to patients and caregivers by offering novel specialty products to satisfy unmet market needs and optimize the prescription journey and patient engagement in the U.S.